Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check24 days agoChange DetectedThe webpage has removed a date reference of January 22, 2025, and added a new date reference of April 17, 2025.SummaryDifference0.7%
- Check31 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0, indicating a significant revision. Additionally, a phrase has been removed and replaced with a similar one, but the core content remains unchanged.SummaryDifference1.0%
- Check38 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 22, 2025.SummaryDifference1.0%
- Check81 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check96 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.